Opinion

Video

The Role of CTLA-4 Inhibitors in NSCLC

Experts on non–small cell lung cancer discuss the role of CTLA-4 inhibitors in the NSCLC treatment landscape.

This is a synopsis of a Peer Exchange video series featuring Benjamin P. Levy, MD, of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Solange Peters, MD, PhD, of University Hospital of Lausanne; Joshua K. Sabari, MD, of NYU Langone’s Perlmutter Cancer Center; Edward B. Garon, MD, MS, of UCLA Jonsson Comprehensive Cancer Center; and Marina Chiara Garassino, MD, of University of Chicago Medicine Comprehensive Cancer Center.

Dr Levy asked Dr Peters about her perspective on incorporating CTLA-4 inhibitors like ipilimumab. She responded that while the data is not high-level evidence, the most consistent finding across multiple trials is benefit in PD-L1–negative patients when adding CTLA-4 inhibitors to chemotherapy/immunotherapy regimens, with similar magnitude as in PD-L1–positive patients. Since PD-L1–negative patients derive little benefit from IO [immuno-oncology] alone, adding CTLA-4 blockade could address this unmet need. Dr Peters also noted possible extra benefit in patients with brain metastases and tumors with STK11/KEAP1 alterations that limit immunogenicity, though prospective data is needed.

Dr Sabari agreed on the rationale but prefers prospective trial data before adding CTLA-4 inhibitor toxicity. He mentioned an ongoing study evaluating chemoimmunotherapy with durvalumab/tremelimumab versus chemotherapy in difficult-to-treat patients with NSCLC [non–small cell lung cancer], including those with STK11/KRAS co-mutations. Dr Garassino concurred that more research focus is still needed on improving outcomes for PD-L1–negative patients, even if CTLA-4 inhibitors provide some benefit.

In summary, the expert panel discussed current evidence and rationale for CTLA-4 inhibitors in first-line NSCLC, particularly for PD-L1–negative patients, while noting the need for further randomized trial data given the added toxicity with CTLA-4 blockade.

*Video synopsis is AI-generated and reviewed by OncLive editorial staff.

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.
Nicolas Girard, MD
5 KOLs are featured in this series.
5 KOLs are featured in this series.